II. Approach
- Assess Current disease activity
- Morning Stiffness
- Synovitis
- Fatigue
- C-Reactive Protein
- Document Joint Damage
- Joint Range of motion and deformities
- XRay joint space narrowing and erosions
- Functional status
- Document Joint Extra-articular manifestations
- Nodules
- Pulmonary fibrosis
- Vasculitis
- Scales to grade current Rheumatoid Arthritis Severity
III. Management: General
- Non-Pharmacologic
- Systemic and articular rest
- Tobacco Cessation
- Tobacco Smoking is associated with more severe RA-related articular and extraarticular disease
- Cardiovascular Risk is significantly increased in RA
- Overall Cardiovascular Risk Reduction is critical
- Physiotherapy
- Physical therapy and hand therapy for joint protection techniques
- Local Heat Therapy
- Local Cold Therapy
- Exercises
- Range of Motion
- Conditioning
- Strengthening Exercises
- Tai Chi
- Assistive Devices
- Patient Education Materials
- Arthritis Foundation
- American College Rheumatology
- Bob and Brad (Youtube)
-
Rheumatoid Arthritis Remittive Medications (DMARDs)
- Most important agents in Rheumatoid Arthritis
- Methotrexate is first-line preferred agent
- Alternatives include Leflunomide, Sulfasalazine, Plaquenil
- Biologic and TNF agents are third-line agents in refractory cases
- Consider tapering DMARD if in remission for at least 6 months (esp. if anti-citrullinated Protein negative)
- In some cases DMARDs may be tapered off with maintained remission
- Haschka (2016) Ann Rheum Dis 75(1):45-51 [PubMed]
-
Rheumatoid Arthritis Antiinflammatory Medications (NSAIDs, COX2 Inhibitors)
- Used in combination with DMARDs
- Limit use of NSAIDs and COX2 Inhibitors once on DMARD >1 month
- Decrease to lowest effective dose (preferably use only as needed)
- Best use is limiting NSAIDS and COX2 Inhibitors for exacerbations
- Other medications
- Atorvastatin
- Showed modest benefit in clinical improvement
- McCarey (2004) Lancet 363:2015-21 [PubMed]
- Atorvastatin
- Joint Replacement
- Consider for severe joint damage with pain refractory to medical management
IV. Management: Initial protocol
- Indications: New moderate to severe seropositive Rheumatoid Arthritis
- Protocol: Start
- Prednisone
- Low dose protocol (preferred if adequate)
- Prednisone 5-10 mg orally daily for 4-6 weeks
- High dose tapering protocol
- Prednisone 60 mg daily tapered weekly by 10 mg each week
- Low dose protocol (preferred if adequate)
- Methotrexate
- Start at 7.5-10 mg weekly and titrate to 15 mg weekly in the first 4-6 weeks
- Folic Acid 1 mg daily
- Prednisone
- References
- Michet (2012) Mayo POIM Conference, Rochester
V. Management: Emergency Department
- Cardiopulmonary presentations
- Myocardial Infarction risk (RR 3)
- Congestive Heart Failure (RR 2)
- Atrial Fibrillation (RR 1.4)
- Pulmonary fibrosis, Pulmonary Hypertension and Right Heart Failure
- Pulmonary Embolism
- Pericardial Effusion
- Pleural Effusion
- Methotrexate induced pulmonary toxicity
- Infectious disease presentations
- Immunosuppression due to RA alone, in addition to medications (e.g. TNF agents, Corticosteroids)
- Pneumonia (including opportunistic lung infections, fungal infections, Legionella, Tuberculosis)
-
Joint Pain presentation
- Exclude Septic Arthritis!
- Diagnosis is often delayed in Rheumatoid Arthritis
- Immunocompromised state results in underwhelming signs (afebrile, minimally Inflamed joint)
- Aspirate suspected joints
- Rheumatoid Arthritis flare (after excluding Septic Joint)
- Prednisone taper from 60 mg to 10 mg over 2 weeks
- Exclude Septic Arthritis!
-
Endotracheal Intubation
- Atlantoaxial subluxation risk
- Risk of secondary cervicomedullary compression and respiratory arrest
-
Temporomandibular Joint
Arthritis
- Decreased mouth opening (see LEMON Mnemonic)
- Intubation Approach
- Maintain inline cervical stabilization during intubation
- Use videolarygnoscopy or fiberoptics to aid intubation
- Atlantoaxial subluxation risk
- References
- Herbert, Orman, Berman in Herbert (2018) EM:Rap 18(4): 6